The agreement does not say how much money changed hands as part of the settlement, but one analyst notes this is the very sort of deal that is likely to draw regulatory scrunity, if the Supreme Court sides with the FTC.
FORBES: AstraZeneca & A Pay-To-Delay Deal The FTC Would Not Like